Precipio (PRPO) Stock Price, News & Analysis

Company Overview

Precipio, Inc. (NASDAQ: PRPO) is a specialty diagnostics company focused on improving outcomes for patients with hematologic and oncologic conditions through rapid, accurate laboratory testing and advanced digital pathology. The company’s core services address the complexities of diagnosing blood cancers and related disorders, combining traditional hematopathology techniques with proprietary technologies designed to enhance sensitivity and specificity. Precipio’s platform covers immunohistochemistry, flow cytometry, fluorescence in situ hybridization (FISH) and molecular assays, enabling clinicians to make informed treatment decisions sooner.

Central to Precipio’s offering is its suite of branded products and technologies, which include automated slide-preparation systems and AI-driven digital pathology tools. These solutions streamline laboratory workflows and support remote consultations, allowing for faster turnaround times. The company also develops specialized reagent kits for immunophenotyping and molecular profiling, which have been integrated into its CLIA-accredited, CAP-accredited laboratories to ensure consistency and compliance with regulatory standards.

Precipio operates multiple U.S.-based laboratories in strategically selected regions, serving community hospitals, academic medical centers and contract research organizations. Through a network of logistics partnerships, the company provides sample collection and shipping services across North America, Europe and parts of Asia, facilitating global access to its diagnostics capabilities. Strategic collaborations with clinical trial sponsors further extend Precipio’s reach into oncology research, offering companion diagnostics and central laboratory services for novel therapeutics.

Founded in the late 2000s and rebranded to Precipio when it went public, the company has been led by CEO Dominic Sciabica, whose background spans over two decades in medical device innovation and commercial leadership. Under his stewardship, Precipio has expanded its technology portfolio and enhanced its digital infrastructure, positioning the company at the intersection of precision medicine and laboratory diagnostics. The management team’s combined expertise in pathology, bioinformatics and regulatory affairs underpins Precipio’s mission to transform hematologic diagnostics worldwide.

Key Stats

• Today's Range: $15.26 to $16.19
• 50-Day Range: $6.30 to $16.20
• 52-Week Range: $3.90 to $16.89
• Volume: 15,347 shs
• Average Volume: 10,485 shs
• Market Capitalization: $23.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Precipio Stock Analysis - MarketRank™

Precipio scored higher than 19% of companies evaluated by MarketBeat, and ranked 922nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Precipio.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Precipio is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Precipio is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Precipio has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.67% of the float of Precipio has been sold short.

Short Interest Ratio / Days to Cover

Precipio has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Precipio has recently increased by 53.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Precipio does not currently pay a dividend.

Dividend Growth

Precipio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.67% of the float of Precipio has been sold short.

Short Interest Ratio / Days to Cover

Precipio has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Precipio has recently increased by 53.57%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.29

News Sentiment

Precipio has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Precipio this week, compared to 0 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Precipio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $135,007.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

16.90% of the stock of Precipio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 10.45% of the stock of Precipio is held by institutions.

PRPO Stock Analysis - Frequently Asked Questions

How have PRPO shares performed this year?

Precipio's stock was trading at $5.54 at the start of the year. Since then, PRPO shares have increased by 181.0% and is now trading at $15.57.

How were Precipio's earnings last quarter?

Precipio, Inc. (NASDAQ:PRPO) posted its quarterly earnings results on Wednesday, May, 14th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $4.93 million for the quarter. Precipio had a negative trailing twelve-month return on equity of 25.87% and a negative net margin of 15.45%.
Read the conference call transcript.

When did Precipio's stock split?

Precipio's stock reverse split on the morning of Friday, September 22nd 2023.The 1-20 reverse split was announced on Friday, September 22nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Precipio?

Shares of PRPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Precipio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Precipio investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:PRPO
• CIK: 1043961
• Web: www.precipiodx.com
• Phone: (203) 787-7888
• Fax: 402-452-5401
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.29 million
• Net Margins: -15.45%
• Pretax Margin: -15.45%
• Return on Equity: -25.87%
• Return on Assets: -17.93%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 0.76
• Quick Ratio: 0.57

Sales & Book Value

• Annual Sales: $18.53 million
• Price / Sales: 1.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.16 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 1,510,000
• Free Float: 1,256,000
• Market Cap: $23.51 million
• Optionable: No Data
• Beta: 1.28